About this benchmarkRheumatoid arthritis · USRheumatologists · USAI answers generated with a US rheumatologist persona4 AI systemsPre-ACR baseline, 30 October 2026

01 · Visibility & Representation

Visibility is only the first lens.

AI speaks molecule, not brand: 6.3% of answers name any in-scope brand.

Adalimumab is named by a brand in 12% of the answers that name it; Humira appears in 2% of all answers.

6.3%

115 of 1,816 answers name an in-scope brand

43 in-scope brands. Brand naming is not preference.

Who AI names

Methotrexate is named in 53% of answers. After it, the order shifts from system to system.

Top 20 of 25 scored therapies, ranked by the share of answers that name them.

AI system

All AI systems · 1,816 answers

  1. 1Methotrexate53% · 971 of 1,816 answers
  2. 2Abatacept38% · 697 of 1,816 answers
  3. 3Rituximab35% · 644 of 1,816 answers
  4. 4Tocilizumab28% · 508 of 1,816 answers
  5. 5Tofacitinib23% · 414 of 1,816 answers
  6. 6Adalimumab21% · 381 of 1,816 answers
  7. 7Upadacitinib20% · 363 of 1,816 answers
  8. 8Baricitinib20% · 355 of 1,816 answers
  9. =9Etanercept18% · 333 of 1,816 answers
  10. =9Sulfasalazine18% · 333 of 1,816 answers
  11. 11Hydroxychloroquine18% · 328 of 1,816 answers
  12. 12Infliximab16% · 290 of 1,816 answers
  13. 13Leflunomide16% · 284 of 1,816 answers
  14. 14Sarilumab12% · 218 of 1,816 answers
  15. 15Certolizumab pegol9% · 168 of 1,816 answers
  16. 16Golimumab8% · 150 of 1,816 answers
  17. 17Prednisone*6% · 101 of 1,816 answers
  18. 18FilgotinibNot approved in the US5% · 93 of 1,816 answers
  19. 19Anakinra2% · 37 of 1,816 answers
  20. 20Prednisolone†1% · 26 of 1,816 answers
Show all 25 scored therapies
  1. 21Rosnilimab‡Investigational1% · 21 of 1,816 answers
  2. 22AB-101Development discontinued (Artiva, 27 Oct 2026)1% · 12 of 1,816 answers
  3. 23GirocitinibInvestigational1% · 10 of 1,816 answers
  4. 24Methylprednisolone†0% · 4 of 1,816 answers
  5. 25IMVT-1402Investigational0% · 3 of 1,816 answers

ChatGPT · 454 answers

  1. 1Abatacept50% · 225 of 454 answers
  2. 2Methotrexate49% · 224 of 454 answers
  3. 3Rituximab44% · 200 of 454 answers
  4. 4Tocilizumab31% · 140 of 454 answers
  5. 5Tofacitinib21% · 94 of 454 answers
  6. 6Adalimumab19% · 88 of 454 answers
  7. =7Upadacitinib19% · 85 of 454 answers
  8. =7Sulfasalazine19% · 85 of 454 answers
  9. 9Hydroxychloroquine18% · 83 of 454 answers
  10. 10Baricitinib18% · 80 of 454 answers
  11. 11Sarilumab17% · 75 of 454 answers
  12. 12Etanercept15% · 68 of 454 answers
  13. 13Leflunomide15% · 67 of 454 answers
  14. 14Infliximab14% · 62 of 454 answers
  15. =15Certolizumab pegol10% · 44 of 454 answers
  16. =15Golimumab10% · 44 of 454 answers
  17. 17FilgotinibNot approved in the US6% · 25 of 454 answers
  18. 18Prednisone*4% · 16 of 454 answers
  19. 19Anakinra2% · 11 of 454 answers
  20. 20Prednisolone†2% · 8 of 454 answers
Show all 25 scored therapies
  1. 21Rosnilimab‡Investigational1% · 4 of 454 answers
  2. 22GirocitinibInvestigational1% · 3 of 454 answers
  3. =23AB-101Development discontinued (Artiva, 27 Oct 2026)0% · 1 of 454 answers
  4. =23Methylprednisolone†0% · 1 of 454 answers
  5. 25IMVT-1402Investigational0% · 0 of 454 answers

Claude · 454 answers

  1. 1Methotrexate49% · 221 of 454 answers
  2. 2Abatacept28% · 125 of 454 answers
  3. 3Tocilizumab26% · 120 of 454 answers
  4. 4Rituximab26% · 119 of 454 answers
  5. 5Adalimumab22% · 101 of 454 answers
  6. 6Etanercept20% · 93 of 454 answers
  7. 7Tofacitinib20% · 90 of 454 answers
  8. =8Baricitinib17% · 75 of 454 answers
  9. =8Infliximab17% · 75 of 454 answers
  10. 10Upadacitinib16% · 71 of 454 answers
  11. 11Leflunomide15% · 68 of 454 answers
  12. 12Sulfasalazine12% · 55 of 454 answers
  13. 13Hydroxychloroquine11% · 52 of 454 answers
  14. =14Certolizumab pegol7% · 32 of 454 answers
  15. =14Golimumab7% · 32 of 454 answers
  16. 16FilgotinibNot approved in the US6% · 25 of 454 answers
  17. 17Prednisone*5% · 23 of 454 answers
  18. 18Sarilumab4% · 20 of 454 answers
  19. 19Anakinra2% · 10 of 454 answers
  20. 20Rosnilimab‡Investigational2% · 8 of 454 answers
Show all 25 scored therapies
  1. 21Prednisolone†1% · 5 of 454 answers
  2. 22AB-101Development discontinued (Artiva, 27 Oct 2026)1% · 4 of 454 answers
  3. 23Methylprednisolone†0% · 2 of 454 answers
  4. 24GirocitinibInvestigational0% · 1 of 454 answers
  5. 25IMVT-1402Investigational0% · 0 of 454 answers

Gemini · 454 answers

  1. 1Methotrexate52% · 237 of 454 answers
  2. =2Abatacept27% · 121 of 454 answers
  3. =2Rituximab27% · 121 of 454 answers
  4. 4Tofacitinib24% · 109 of 454 answers
  5. =5Tocilizumab23% · 104 of 454 answers
  6. =5Upadacitinib23% · 104 of 454 answers
  7. 7Baricitinib21% · 94 of 454 answers
  8. 8Adalimumab17% · 77 of 454 answers
  9. 9Hydroxychloroquine17% · 75 of 454 answers
  10. 10Sulfasalazine16% · 72 of 454 answers
  11. 11Etanercept15% · 70 of 454 answers
  12. 12Infliximab12% · 55 of 454 answers
  13. 13Leflunomide12% · 54 of 454 answers
  14. 14Sarilumab7% · 34 of 454 answers
  15. 15Certolizumab pegol7% · 33 of 454 answers
  16. 16Prednisone*6% · 26 of 454 answers
  17. 17Golimumab5% · 22 of 454 answers
  18. 18FilgotinibNot approved in the US2% · 10 of 454 answers
  19. 19Prednisolone†2% · 7 of 454 answers
  20. =20Anakinra1% · 6 of 454 answers
Show all 25 scored therapies
  1. =20AB-101Development discontinued (Artiva, 27 Oct 2026)1% · 6 of 454 answers
  2. =22Rosnilimab‡Investigational1% · 4 of 454 answers
  3. =22GirocitinibInvestigational1% · 4 of 454 answers
  4. 24IMVT-1402Investigational0% · 2 of 454 answers
  5. 25Methylprednisolone†0% · 0 of 454 answers

Perplexity · 454 answers

  1. 1Methotrexate64% · 289 of 454 answers
  2. 2Abatacept50% · 226 of 454 answers
  3. 3Rituximab45% · 204 of 454 answers
  4. 4Tocilizumab32% · 144 of 454 answers
  5. =5Tofacitinib27% · 121 of 454 answers
  6. =5Sulfasalazine27% · 121 of 454 answers
  7. 7Hydroxychloroquine26% · 118 of 454 answers
  8. 8Adalimumab25% · 115 of 454 answers
  9. 9Baricitinib23% · 106 of 454 answers
  10. 10Upadacitinib23% · 103 of 454 answers
  11. 11Etanercept22% · 102 of 454 answers
  12. 12Infliximab22% · 98 of 454 answers
  13. 13Leflunomide21% · 95 of 454 answers
  14. 14Sarilumab20% · 89 of 454 answers
  15. 15Certolizumab pegol13% · 59 of 454 answers
  16. 16Golimumab11% · 52 of 454 answers
  17. 17Prednisone*8% · 36 of 454 answers
  18. 18FilgotinibNot approved in the US7% · 33 of 454 answers
  19. 19Anakinra2% · 10 of 454 answers
  20. 20Prednisolone†1% · 6 of 454 answers
Show all 25 scored therapies
  1. 21Rosnilimab‡Investigational1% · 5 of 454 answers
  2. 22GirocitinibInvestigational0% · 2 of 454 answers
  3. =23AB-101Development discontinued (Artiva, 27 Oct 2026)0% · 1 of 454 answers
  4. =23Methylprednisolone†0% · 1 of 454 answers
  5. =23IMVT-1402Investigational0% · 1 of 454 answers
  • AI Visibility = share of all 1,816 answers naming the therapy (molecule or brand). Reflects the mix of questions, not preference.
  • * Counts the molecule name only. Generic references such as "glucocorticoids" or "steroids" are not counted, so this is not a measure of corticosteroid mentions overall.
  • † Molecule name only; see prednisone caveat.
  • ‡ Mostly named in prompts that ask about investigational therapies. 3 answers misspell it "rosinilimab" and are not counted.

Differences between AI systems are mostly differences in breadth: Perplexity names 4.7 scored therapies per answer on average, Claude 3.1.

Abatacept appears in 28% of Claude and 27% of Gemini answers, but in 50% of ChatGPT and 50% of Perplexity answers.

Benchmark your therapy's AI visibility against competitors, system by system.

Schedule a meeting

Prominence

Visible is not the same as first.

Methotrexate is named in 53.5% of answers and is named first in 41.0% of the answers that name any scored therapy.

AI Visibility
Of all 1,816 answers: is the therapy named at all?
Named first
Of the 1,496 answers naming any scored therapy: does it come first?

Two different bases. Read the bars side by side; neither is a share of the other.

  • AI Visibility · 1,816 answers
  • Named first · 1,496 answers

  1. Methotrexate971 of 1,816 · 614 of 1,496 answers

  2. Abatacept697 of 1,816 · 130 of 1,496 answers

  3. Rituximab644 of 1,816 · 117 of 1,496 answers

  4. Tofacitinib414 of 1,816 · 116 of 1,496 answers

  5. Tocilizumab508 of 1,816 · 99 of 1,496 answers

  6. Adalimumab381 of 1,816 · 87 of 1,496 answers

  7. Infliximab290 of 1,816 · 68 of 1,496 answers

  8. Hydroxychloroquine328 of 1,816 · 67 of 1,496 answers

  9. Upadacitinib363 of 1,816 · 39 of 1,496 answers

  10. Etanercept333 of 1,816 · 37 of 1,496 answers

  • Shown for the ten therapies named first most often. The other fifteen are not shown, which does not mean they are never named first.
  • All four AI systems combined; this measurement has no per-system order of mention.

Brands and molecules

When AI compares brands, it calls them equal more often than not.

Of 140 brand-versus-brand judgments, 57% were judged equal, 24% showed no clear preference and only 4 were clear.

  • Clear4 · 3%
  • Equal80 · 57%
  • Conditional3 · 2%
  • No clear preference34 · 24%
  • One-sided19 · 14%

Where AI differentiates biosimilars it cites FDA interchangeability, formulary and formulation. Biosimilarity and interchangeability are different FDA designations.

Answers naming a therapy that use a brand name

Each figure is a share of the answers that name that therapy.

  1. Methotrexate0%1 of 971 answers naming it
  2. Abatacept4%31 of 697 answers naming it
  3. Rituximab4%25 of 644 answers naming it
  4. Tocilizumab6%29 of 508 answers naming it
  5. Tofacitinib8%34 of 414 answers naming it
  6. Adalimumab12%46 of 381 answers naming it
  7. Upadacitinib8%30 of 363 answers naming it
  8. Baricitinib8%28 of 355 answers naming it
  9. Sulfasalazine0%1 of 333 answers naming it
  10. Etanercept8%25 of 333 answers naming it
  11. Hydroxychloroquine1%3 of 328 answers naming it
  12. Infliximab11%32 of 290 answers naming it
  13. Leflunomide1%4 of 284 answers naming it
  14. Sarilumab4%8 of 218 answers naming it
  15. Certolizumab pegol6%10 of 168 answers naming it
  16. Golimumab18%27 of 150 answers naming it
  17. Filgotinib1%1 of 93 answers naming it
  18. Anakinra5%2 of 37 answers naming it

How current is the picture?

A pre-ACR baseline, to be re-measured after ACR.

Rosnilimab is named in 21 of 1,816 answers (14 of 76 in questions about investigational therapies); AB-101 in 12 (10 of 76); girocitinib in 10 (10 of 76); IMVT-1402 in 3 (3 of 76).

TherapyStatusAnswers naming it, of 1,816In questions about investigational therapies, of 76
RosnilimabInvestigational2114
AB-101Development discontinued (Artiva, 27 Oct 2026)1210
GirocitinibInvestigational1010
IMVT-1402Investigational33

Information freshness

AB-101 development was discontinued on 27 Oct 2026, three days before collection. Of 8 answers to the two AB-101 questions, 3 mention the discontinuation: Gemini 2 of 2, Claude 1 of 2, ChatGPT 0 of 2, Perplexity 0 of 2.

  • ChatGPT0 of 2
  • Claude1 of 2
  • Gemini2 of 2
  • Perplexity0 of 2

Artiva Biotherapeutics disclosure, 27 October 2026

  • A low figure here describes AI answers on one date, not the therapy.
  • Other investigational agents AI mentions (e.g. zemprocitinib, peficitinib, olokizumab) were not in the scored universe and are not ranked.

What this means

For brand and omnichannel leads

In this benchmark, AI answers name the molecule far more often than any brand. Brand teams should not assume that brand messaging carries into AI answers about their therapy.

What limits this reading

Visibility counts every mention, including cautionary and historical ones. It is not efficacy, safety or preference, and one collection date is a baseline, not a trend.

The Theralexis capability

Theralexis measures visibility, order of mention and brand-versus-molecule naming for your therapy and your competitors, in your markets, system by system.

Your portfolio

Discuss your competitive AI representation

See how often AI names your therapy, in which systems, how often first, and whether it ever uses your brand.

Schedule a meeting

About this benchmark

What was measured

AI representation analysis of 1,816 answers to US rheumatologist-style open questions and 960 answers to comparative questions from four web-enabled AI systems (ChatGPT, Claude, Gemini, Perplexity), collected 30 October 2026 with a US rheumatologist persona. Visibility = share of answers naming a therapy. Neither visibility, order of mention nor head-to-head verdicts indicate clinical efficacy, safety, preference or recommendation.

Pre-ACR baseline (v1.1 corrected analytical view, 30 Oct 2026). Re-measured after ACR Convergence 2026.

Full methodology

Sources and scope
Publisher
Theralexis
Market
Rheumatoid arthritis · United States
Persona
AI answers generated with a US rheumatologist persona
Open questions
454 questions · 1,816 answers
Comparative questions
240 questions · 960 answers
Measured
Published
AI systems
ChatGPT (GPT-5.4-mini), Claude (Claude Haiku 4.5), Gemini (Gemini 3.1 Flash-Lite), Perplexity (Sonar)
Head-to-head judge
gpt-4.1-mini